But funding proposals to US agencies also tend to be more similar to previously funded projects if they are written or edited ...
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy TA1126 28 January 2026 28 January 2026 Concizumab for treating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results